Compare VECO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VECO | GLPG |
|---|---|---|
| Founded | 1945 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1994 | 2005 |
| Metric | VECO | GLPG |
|---|---|---|
| Price | $30.90 | $31.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | $28.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 632.4K | 102.2K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $681,408,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | $9.81 | N/A |
| P/E Ratio | $36.86 | ★ N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $16.92 | $22.36 |
| 52 Week High | $34.45 | $37.78 |
| Indicator | VECO | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 45.01 |
| Support Level | $31.49 | $31.41 |
| Resistance Level | $33.41 | $32.75 |
| Average True Range (ATR) | 1.12 | 0.52 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 53.69 | 11.32 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The majority of the company's revenue is generated from sales to the Semiconductor Industry and within China.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.